All News
Metformin Reduces Osteoarthritis Risk in NIDDM Patients
Osteoarthritis is a common chronic condition that usually causes joint pain and can be severe enough to require knee and hip replacements.
Read Article
Best of 2022: Approach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
Read Article
COVID-19 Vaccine Responses in Rheumatic Disease Patients
Nature Reviews Rheumatology features a review of three notable papers that address the impact of SARS-CoV-2 vaccination on people with inflammatory rheumatic disease.
Read Article
JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD
The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.
Read Article
ACR New Guidelines on Integrative Approach to RA
The American College of Rheumatology (ACR) released a summary of its new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis.
Read Article
Marginal Benefit with Diet and Exercise in Obese Knee Osteoarthritis Patients
The easiest intervention for knee osteoarthritis (diet and exercise) is also the most difficult for many patients; but do these work? A new study of a weight loss and exercise program in community settings shows only marginal benefits.
Read Article
Efgartigimod Treatment in Chronic Primary ITP
Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results repor
Read Article
2022 ACR/EULAR Giant Cell Arteritis Classification Criteria
Giant cell arteritis (GCA) has historically been a clinical diagnosis (visual loss, headache, jaw pain, scalp tenderness, etc) supported by labs and histopathology.
Read Article
Telemedicine Updates
Several recent articles inform us of recent trends in Telemedicine.
Read Article
Xeljanz Cancer Risks Detailed
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
Read Article
Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis
Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.
Read Article
Multi-ancestry analysis reveals novel genetic loci associated with Osteoarthritis
The first large multi-ancestry genetics study of osteoarthritis (OA) has found 10 novel OA-associated genetic loci, and results showed some of the OA-associated regions are robustly found in every population ancestry studied.
Read Article
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.
Read Article
Rheum Drugs & IDSA Guidelines to Treat COVID-19
The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.
Read Article
RECITAL Trial: RTX vs. CTX in CTD-ILD
A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX.
Read Article
Just Can’t Get Enough of Hydroxychloroquine
When it comes to hydroxychloroquine dosing, issues on efficacy, toxicity and therapeutic thresholds may affect the optimal use of this important drug.
Following are three abstracts presented during the meeting that address these topics.
Low Dose IL-2 Therapy in Sjögren’s
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
Read Article
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
Read Article
How Underweight Women Can Reduce Hip Fracture Risk
How women can reduce the risk of hip fracture?
Read Article
Will a vegetarian diet and exercise actually help RA disease activity?
The exact role of diet, physical activity, and stress management in the management of RA has long been debated. While reasonable evidence has supported the importance of physical activity in patients with RA, its capacity to reduce disease activity via conventional measures such as DAS28 was less well delineated.
Read Article
